Reprogramming CAR-T Cell Therapy for Solid Tumors: Combination Strategies to Overcome Resistance

Authors

  • Wei Cheng Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Guangzhou Medical University
  • Mei-Lan Liu The Third Clinical School of Guangzhou Medical University
  • Yu-Hua Diao Department of Dermatology, Burns and Plastic Surgery, Xijing 986 Hospital Department, Fourth Military Medical University
  • Bing-Kun Chen Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Guangzhou Medical University
  • Yi-Peng Wen The Third Clinical School of Guangzhou Medical University, Guangzhou Medical University
  • Chi Zhang KingMed School of Laboratory Medicine, Guangzhou Medical University
  • Man-Ting Liu Department of Radiology, Central Laboratory, the Second Affiliated Hospital, Guangzhou Medical University
  • Zi-Qi Shao
  • Jian-Yu Cai Scientific Research Center, Guangzhou Medical University
  • Bihui Cao Guangdong Provincial People's Hospital

DOI:

https://doi.org/10.66505/cbtt.v1i3.47

Keywords:

Chimeric antigen receptor T cells , CAR-T, tumor microenvironment, immunotherapy, immune checkpoint blockade, multi-antigen targeting, cellular immunotherapy, synthetic biology

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has achieved unprecedented clinical success in hematologic malignancies, yet translating these outcomes to solid tumors has proven substantially more challenging. Unlike blood cancers, solid tumors present multiple interconnected barriers, including antigen heterogeneity, inefficient trafficking and infiltration, physical stromal constraints, metabolic competition, and profoundly immunosuppressive tumor microenvironments that collectively limit CAR-T cell persistence and function. Increasing evidence indicates that no single engineering modification is sufficient to overcome these obstacles, driving the development of combination strategies that integrate CAR-T cells with immune checkpoint blockade, cytokine and chemokine modulation, targeted therapies, radiotherapy, oncolytic viruses, cancer vaccines, biomaterial-based delivery platforms, and next-generation synthetic biology approaches. Concurrent advances in armored CAR-T cells, logic-gated circuits, multi-antigen targeting systems, and non-viral gene engineering are enabling more precise, adaptable, and controllable cellular therapies. In this review, we examine the biological mechanisms underlying resistance to CAR-T therapy in solid tumors and critically evaluate emerging combination strategies designed to enhance tumor recognition, trafficking, persistence, and antitumor activity. We further discuss translational challenges, including manufacturing complexity, toxicity management, and patient selection, and propose a framework for developing precision combination CAR-T therapies tailored to the unique biology of individual tumors. Collectively, these advances are reshaping CAR-T cell therapy from a single-agent cellular intervention into a programmable, increasingly integrated platform for solid-tumor immunotherapy.

References

1. Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther. 2023;8(1):306. doi:10.1038/s41392-023-01521-5

2. Mulvey A, Trueb L, Coukos G, Arber C. Novel strategies to manage CAR-T cell toxicity. Nat Rev Drug Discov. 2025;24(5):379-397. doi:10.1038/s41573-024-01100-5

3. Bock TJ, Colonne CK, Fiorenza S, Turtle CJ. Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma. Nat Rev Clin Oncol. 2025;22(4):241-261. doi:10.1038/s41571-025-00992-5

4. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7

5. Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20(7):531-550. doi:10.1038/s41573-021-00189-2

6. Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2025;43(4):506-515. doi:10.1038/s41587-024-02446-2

7. Albarrán-Fernández V, Angelats L, Delgado J, Gros A, Urbano-Ispizua Á, Guedan S, et al. Unlocking the potential of engineered immune cell therapy for solid tumors. Nat Commun. 2025;16(1):1144. doi:10.1038/s41467-025-56527-0

8. Cao B, Liu M, Xiao Z, Leng D, Zhou Y, Zhang Z, et al. CV1-secreting sCAR-T cells potentiate the abscopal effect of microwave ablation in heterogeneous tumors. Cell Rep Med. 2025;6(2):101965. doi:10.1016/j.xcrm.2025.101965

9. Cao B, Liu M, Wang L, Zhu K, Cai M, Chen X, et al. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer. Nat Commun. 2022;13(1):6203. doi:10.1038/s41467-022-33968-5

10. Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42(11):1825-1863. doi:10.1016/j.ccell.2024.09.010

11. Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25(5):353-369. doi:10.1038/s41577-024-01111-8

12. Vendramin R, Litchfield K, Swanton C. Cancer evolution: Darwin and beyond. EMBO J. 2021;40(18):e108389. doi:10.15252/embj.2021108389

13. Milo I, Bedora-Faure M, Garcia Z, Thibaut R, Périé L, Shakhar G, et al. The immune system profoundly restricts intratumor genetic heterogeneity. Sci Immunol. 2018;3(29):eaat1435. doi:10.1126/sciimmunol.aat1435

14. Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther. 2025;10(1):227. doi:10.1038/s41392-025-02280-1

15. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851. doi:10.1038/mt.2010.24

16. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904-912. doi:10.1038/mt.2013.17

17. Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother. 2017;66(11):1425-1436. doi:10.1007/s00262-017-2034-7

18. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33(15):1688-1696. doi:10.1200/JCO.2014.58.0225

19. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678-689. doi:10.1038/nri2156

20. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401-410. doi:10.1038/nrc1093

21. Ma W, Wang Y, Zhang R, Yang F, Zhang D, Huang M, et al. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. Nat Cancer. 2021;2(1):83-97. doi:10.1038/s43018-020-00147-8

22. Lamplugh ZL, Wellhausen N, June CH, Fan Y. Microenvironmental regulation of solid tumour resistance to CAR T cell therapy. Nat Rev Immunol. 2026;26(3):230-248. Epub 2025 Oct 14. doi:10.1038/s41577-025-01229-3

23. Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol. 2021;18(8):527-540. doi:10.1038/s41571-021-00496-y

24. Cho Y, Doh J. The extracellular matrix in solid tumor immunotherapy. Trends Immunol. 2024;45(9):705-714. doi:10.1016/j.it.2024.07.009

25. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol. 1998;16(7):387-398. doi:10.1016/S0945-053X(98)90012-9

26. Vilgelm AE, Richmond A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Front Immunol. 2019;10:333. doi:10.3389/fimmu.2019.00333

27. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69(7):3077-3085. doi:10.1158/0008-5472.CAN-08-2281

28. Tian Y, Zhang L, Ping Y, Zhang Z, Yao C, Shen C, et al. CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors. Cancer Immunol Immunother. 2025;74(2):55. doi:10.1007/s00262-024-03909-w

29. Mowat C, Mosley SR, Namdar A, Schiller D, Baker K. Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10. J Exp Med. 2021;218(9):e20210108. doi:10.1084/jem.20210108

30. Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085-1095. doi:10.1038/s41423-021-00655-2

31. Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022;3(3):100543. doi:10.1016/j.xcrm.2022.100543

32. Hori S. FOXP3 as a master regulator of Treg cells. Nat Rev Immunol. 2021;21(10):618-619. doi:10.1038/s41577-021-00598-9

33. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109-118. doi:10.1038/cr.2016.151

34. Imianowski CJ, Chen Q, Workman CJ, Vignali DAA. Regulatory T cells in the tumour microenvironment. Nat Rev Cancer. 2025;25(9):703-722. doi:10.1038/s41568-025-00832-9

35. Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023;8(1):235. doi:10.1038/s41392-023-01471-y

36. Itahashi K, Irie T, Yuda J, Kumagai S, Tanegashima T, Lin YT, et al. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci Immunol. 2022;7(76):eabk0957. doi:10.1126/sciimmunol.abk0957

37. Alvisi G, Brummelman J, Puccio S, Mazza EM, Tomada EP, Losurdo A, et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J Clin Invest. 2020;130(6):3137-3150. doi:10.1172/JCI130426

38. Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, et al. Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection. Immunity. 2014;40(2):289-302. doi:10.1016/j.immuni.2014.01.005

39. Gunderson AJ, Yamazaki T, McCarty K, Fox N, Phillips M, Alice A, et al. TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking. Nat Commun. 2020;11(1):1749. doi:10.1038/s41467-020-15404-8

40. Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, et al. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20(6):724-735. doi:10.1038/s41590-019-0346-9

41. Wei X, Zhang J, Gu Q, Huang M, Zhang W, Guo J, et al. Reciprocal expression of IL-35 and IL-10 defines two distinct effector Treg subsets that are required for maintenance of immune tolerance. Cell Rep. 2017;21(7):1853-1869. doi:10.1016/j.celrep.2017.10.090

42. Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024;187(16):4373-4388.e15. doi:10.1016/j.cell.2024.06.036

43. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989-1004. doi:10.1016/j.immuni.2016.05.001

44. Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957. doi:10.1136/jitc-2020-000957

45. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503-513. doi:10.1016/j.immuni.2004.08.010

46. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257-1265. doi:10.1084/jem.20062512

47. Busse D, de la Rosa M, Hobiger K, Thurley K, Flossdorf M, Scheffold A, et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc Natl Acad Sci U S A. 2010;107(7):3058-3063. doi:10.1073/pnas.0812851107

48. Barthlott T, Moncrieffe H, Veldhoen M, Atkins CJ, Christensen J, O'Garra A, et al. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int Immunol. 2005;17(3):279-288. doi:10.1093/intimm/dxh207

49. Seo SK, Kwon B. Immune regulation through tryptophan metabolism. Exp Mol Med. 2023;55(7):1371-1379. doi:10.1038/s12276-023-01028-7

50. Kennedy PT, Saulters EL, Duckworth AD, Lim YJ, Woolley JF, Slupsky JR, et al. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. Mol Ther. 2024;32(2):457-468. doi:10.1016/j.ymthe.2023.11.028

51. Volpe E, Sambucci M, Battistini L, Borsellino G. Fas-Fas ligand: checkpoint of T cell functions in multiple sclerosis. Front Immunol. 2016;7:382. doi:10.3389/fimmu.2016.00382

52. Cinier J, Hubert M, Besson L, Di Roio A, Rodriguez C, Lombardi V, et al. Recruitment and expansion of Treg cells in the tumor environment—how to target them? Cancers (Basel). 2021;13(8):1850. doi:10.3390/cancers13081850

53. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49-61. doi:10.1016/j.immuni.2014.06.010

54. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108-119. doi:10.1038/s41590-017-0022-x

55. Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer. Trends Immunol. 2019;40(4):310-327. doi:10.1016/j.it.2019.02.003

56. Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485-498. doi:10.1038/s41577-020-00490-y

57. Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635-648. doi:10.1038/s41586-023-05707-3

58. Kouro T, Himuro H, Sasada T. Exhaustion of CAR T cells: potential causes and solutions. J Transl Med. 2022;20(1):239. doi:10.1186/s12967-022-03442-3

59. Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, et al. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun. 2020;11(1):4520. doi:10.1038/s41467-020-18298-8

60. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6(6):e1792. doi:10.1038/cddis.2015.162

61. Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res. 2014;74(24):7185-7190. doi:10.1158/0008-5472.CAN-14-2598

62. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011;208(7):1367-1376. doi:10.1084/jem.20110278

63. Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, et al. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15(1):77. doi:10.1186/s13045-022-01292-6

64. Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun (Lond). 2022;42(11):1112-1140. doi:10.1002/cac2.12345

65. Beckermann KE, Dudzinski SO, Rathmell JC. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev. 2017;35:7-14. doi:10.1016/j.cytogfr.2017.04.003

66. Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105. doi:10.1186/s13045-024-01625-7

67. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227-242. doi:10.1038/nri3405

68. Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380-390. doi:10.1016/j.immuni.2016.01.021

69. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581-590. doi:10.1038/nm.3838

70. Xu Y, Chaudhury A, Zhang M, Savoldo B, Metelitsa LS, Rodgers J, et al. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J Clin Invest. 2016;126(7):2678-2688. doi:10.1172/JCI85834

71. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A. 2008;105(22):7797-7802. doi:10.1073/pnas.0800928105

72. Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36:411-433. doi:10.1146/annurev-immunol-042617-053352

73. Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. 2024;42(8):1319-1325. doi:10.1016/j.ccell.2024.07.002

74. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350-354. doi:10.1038/nature05115

75. Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56(10):2388-2407.e9. doi:10.1016/j.immuni.2023.09.001

76. Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97-111. doi:10.1111/imr.12520

77. Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415-1422. doi:10.1038/s41590-023-01569-z

78. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434-452. doi:10.1016/j.immuni.2018.03.014

79. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. doi:10.1056/NEJMoa1003466

80. Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377-2385. doi:10.1093/annonc/mdx286

81. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130-3144. doi:10.1172/JCI83092

82. Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, et al. PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer. Clin Cancer Res. 2020;26(22):6003-6016. doi:10.1158/1078-0432.CCR-20-1523

83. Mu J, Deng H, Lyu C, Yuan J, Li Q, Wang J, et al. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden. Hematol Oncol. 2023;41(2):275-284. doi:10.1002/hon.2981

84. Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O'Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748-2763. doi:10.1158/2159-8290.CD-21-0407

85. Ni JJ, Zhang ZZ, Ge MJ, Chen JY, Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. Acta Pharmacol Sin. 2023;44(2):288-307. doi:10.1038/s41401-022-00953-z

86. Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146-3162. doi:10.1016/j.ymthe.2023.09.021

87. Prasad K, Cross RS, Jenkins MR. Progress in the development of cytokine-armed CAR T cells. Nat Rev Immunol. 2026. doi:10.1038/s41577-026-01280-8

88. Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, et al. Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J Immunol. 2019;203(1):198-207. doi:10.4049/jimmunol.1800033

89. Ng BD, Rajagopalan A, Kousa AI, Fischman JS, Chen S, Massa A, et al. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Blood. 2024;144(2):171-186. doi:10.1182/blood.2023022293

90. Bell M, Gottschalk S. Engineered cytokine signaling to improve CAR T cell effector function. Front Immunol. 2021;12:684642. doi:10.3389/fimmu.2021.684642

91. Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847-856. doi:10.1038/nbt.4195

92. Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28(4):724-734. doi:10.1038/s41591-022-01726-1

93. Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637(8047):940-946. doi:10.1038/s41586-024-08261-8

94. Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290-1298. doi:10.1056/NEJMoa2314390

95. Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7(1):331. doi:10.1038/s41392-022-01136-2

96. Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther. 2017;25(9):2214-2224. doi:10.1016/j.ymthe.2017.05.012

97. Zheng W, Jones LL, Geiger TL. Modulation of PI3K signaling to improve CAR T cell function. Oncotarget. 2018;9(88):35807-35808. doi:10.18632/oncotarget.26334

98. Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update. Pharmacol Res. 2026;224:108107. doi:10.1016/j.phrs.2026.108107

99. Wang X, Tao X, Chen P, Jiang P, Li W, Chang H, et al. MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB. Signal Transduct Target Ther. 2024;9(1):293. doi:10.1038/s41392-024-01986-y

100. Song F, Tsahouridis O, Stucchi S, Walhart T, Mendell S, Hardy PB, et al. A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells. Nat Immunol. 2025;26(2):279-293. doi:10.1038/s41590-024-02042-1

101. Forsberg M, Konopleva M. AML treatment: conventional chemotherapy and emerging novel agents. Trends Pharmacol Sci. 2024;45(5):430-448. doi:10.1016/j.tips.2024.03.005

102. Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1876-1887. doi:10.1182/blood-2018-11-887067

103. Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024;5(6):880-894. doi:10.1038/s43018-024-00749-6

104. Barber-Rotenberg JS, Haas AR, Aggarwal C, O’Hara M, Hexner E, Pequignot E, et al. Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. Mol Ther. 2026;34(5):2653-2665. doi:10.1016/j.ymthe.2026.01.021

105. Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12(1):409. doi:10.1038/s41467-020-20696-x

106. Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19(5):342-355. doi:10.1038/s41571-022-00607-3

107. Lynch C, Pitroda SP, Weichselbaum RR. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024;25(8):e352-e362. doi:10.1016/S1470-2045(24)00075-5

108. Szlasa W, Sztuder A, Kaczmar-Dybko A, Maciejczyk A, Dybko J. Efficient combination of radiotherapy and CAR-T: a systematic review. Biomed Pharmacother. 2024;174:116532. doi:10.1016/j.biopha.2024.116532

109. Amit U, Uslu U, Verginadis II, Kim MM, Motlagh SAO, Diffenderfer ES, et al. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2024;121(31):e2403002121. doi:10.1073/pnas.2403002121

110. Yang Y, Xu B, Zhu H, Sun W, Liang A, Luo J. Combining CAR-T therapy with radiotherapy or not in refractory/relapsed diffuse large B-cell lymphoma: a comparative study. Clin Transl Radiat Oncol. 2025;55:101041. doi:10.1016/j.ctro.2025.101041

111. Ni H, Reitman ZJ, Zou W, Akhtar MN, Paul R, Huang M, et al. FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy. Nat Cancer. 2025;6(3):460-473. doi:10.1038/s43018-025-00905-6

112. DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK, et al. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther. 2018;26(11):2542-2552. doi:10.1016/j.ymthe.2018.09.008

113. Quach HT, Skovgard MS, Villena-Vargas J, Bellis RY, Chintala NK, Amador-Molina A, et al. Tumor-targeted nonablative radiation promotes solid tumor CAR T-cell therapy efficacy. Cancer Immunol Res. 2023;11(10):1314-1331. doi:10.1158/2326-6066.CIR-22-0840

114. Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011;258(2):351-369. doi:10.1148/radiol.10081634

115. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199-208. doi:10.1038/nrc3672

116. Albadawi H, Zhang Z, Altun I, Hu J, Jamal L, Ibsen KN, et al. Percutaneous liquid ablation agent for tumor treatment and drug delivery. Sci Transl Med. 2021;13(580):eabe3889. doi:10.1126/scitranslmed.abe3889

117. Huang RS, Chow R, Benour A, Chen D, Boldt G, Wallis CJD, et al. Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2025;26(3):387-398. doi:10.1016/S1470-2045(24)00731-9

118. Grimmett E, Al-Share B, Alkassab MB, Zhou RW, Desai A, Rahim MMA, et al. Cancer vaccines: past, present and future; a review article. Discov Oncol. 2022;13(1):31. doi:10.1007/s12672-022-00491-4

119. Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186(15):3148-3165.e20. doi:10.1016/j.cell.2023.06.002

120. Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl Med. 2020;12(559):eaaz1863. doi:10.1126/scitranslmed.aaz1863

121. Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365(6449):162-168. doi:10.1126/science.aav8692

122. Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844-2853. doi:10.1038/s41591-023-02612-0

123. Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156. doi:10.1038/s41392-023-01407-6

124. Li YR, Lyu Z, Shen X, Fang Y, Yang L. Boosting CAR-T cell therapy through vaccine synergy. Trends Pharmacol Sci. 2025;46(2):180-199. doi:10.1016/j.tips.2024.12.004

125. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642-662. doi:10.1038/nrd4663

126. Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18(8):498-513. doi:10.1038/s41577-018-0014-6

127. Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. The advent of oncolytic virotherapy in oncology: the Rigvir® story. Eur J Pharmacol. 2018;837:117-126. doi:10.1016/j.ejphar.2018.08.042

128. Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18(2):171-176. doi:10.2174/1568009618666171129221503

129. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780-2788. doi:10.1200/JCO.2014.58.3377

130. Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28(8):1630-1639. doi:10.1038/s41591-022-01897-x

131. Chen T, Ding X, Liao Q, Gao N, Chen Y, Zhao C, et al. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J Immunother Cancer. 2021;9(1):e001647. doi:10.1136/jitc-2020-001647

132. Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, et al. Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol Ther. 2020;28(5):1251-1262. doi:10.1016/j.ymthe.2020.02.016

133. Marsico G, Gc S, Siciliano V. Synthetic biology and biomaterials strategies to deceive the tumor microenvironment in CAR-T immunotherapy. Small. 2025;21(39):e06429. doi:10.1002/smll.202506429

134. Cameron DE, Bashor CJ, Collins JJ. A brief history of synthetic biology. Nat Rev Microbiol. 2014;12(5):381-390. doi:10.1038/nrmicro3239

135. Vogt KC, Silberman PC, Lin Q, Han JE, Laflin A, Gellineau HA, et al. Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Sci Adv. 2025;11(4):eads3403. doi:10.1126/sciadv.ads3403

136. Jo Y, Shim JA, Jeong JW, Kim H, Lee SM, Jeong J, et al. Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8+ T and CAR-T cells. Mol Ther. 2024;32(11):3879-3894. doi:10.1016/j.ymthe.2024.08.019

137. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770-779. doi:10.1016/j.cell.2016.01.011

138. Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6:7458. doi:10.1038/ncomms8458

139. Kosti P, Opzoomer JW, Larios-Martinez KI, Henley-Smith R, Scudamore CL, Okesola M, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2021;2(4):100227. doi:10.1016/j.xcrm.2021.100227

140. Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):aab4077. doi:10.1126/science.aab4077

141. Miller IC, Zamat A, Sun LK, Phuengkham H, Harris AM, Gamboa L, et al. Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nat Biomed Eng. 2021;5(11):1348-1359. doi:10.1038/s41551-021-00781-2

142. Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2015;33(1):97-101. doi:10.1038/nbt.3104

143. Feng Y, Tang Q, Wang B, Yang Q, Zhang Y, Lei L, et al. Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. J Nanobiotechnology. 2024;22(1):737. doi:10.1186/s12951-024-03005-2

144. Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci U S A. 2019;116(16):7624-7631. doi:10.1073/pnas.1817147116

145. Gamboa L, Zamat AH, Thiveaud CA, Lee HJ, Kulaksizoglu E, Zha Z, et al. Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens. Nat Cancer. 2025;6(6):1073-1087. doi:10.1038/s43018-025-00968-5

146. Ma W, Zhu D, Li J, Chen X, Xie W, Jiang X, et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics. 2020;10(3):1281-1295. doi:10.7150/thno.40291

147. Qin YT, Li YP, He XW, Wang X, Li WY, Zhang YK. Biomaterials promote in vivo generation and immunotherapy of CAR-T cells. Front Immunol. 2023;14:1165576. doi:10.3389/fimmu.2023.1165576

148. Wang K, Chen Y, Ahn S, Zheng M, Landoni E, Dotti G, et al. GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Nat Cancer. 2020;1(10):990-997. doi:10.1038/s43018-020-00119-y

149. Grosskopf AK, Labanieh L, Klysz DD, Roth GA, Xu P, Adebowale O, Gale EC, et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci Adv. 2022;8(14):eabn8264. doi:10.1126/sciadv.abn8264

150. Hu Q, Li H, Archibong E, Chen Q, Ruan H, Ahn S, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021;5(9):1038-1047. doi:10.1038/s41551-021-00712-1

151. Agarwalla P, Ogunnaike EA, Ahn S, Froehlich KA, Jansson A, Ligler FS, et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat Biotechnol. 2022;40(8):1250-1258. doi:10.1038/s41587-022-01245-x

152. Majedi FS, Hasani-Sadrabadi MM, Thauland TJ, Li S, Bouchard LS, Butte MJ. T-cell activation is modulated by the 3D mechanical microenvironment. Biomaterials. 2020;252:120058. doi:10.1016/j.biomaterials.2020.120058

153. Hyun J, Kim SJ, Cho SD, Kim HW. Mechano-modulation of T cells for cancer immunotherapy. Biomaterials. 2023;297:122101. doi:10.1016/j.biomaterials.2023.122101

154. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85-96. doi:10.1038/s41577-021-00547-6

155. Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501-521. doi:10.1038/s41571-024-00903-0

156. Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390(7):584-586. doi:10.1056/NEJMp2400209

157. Sheridan C. Why gene therapies must go virus-free. Nat Biotechnol. 2023;41(6):737-739. doi:10.1038/s41587-023-01824-6

158. Wang C, Pan C, Yong H, Wang F, Bo T, Zhao Y, et al. Emerging non-viral vectors for gene delivery. J Nanobiotechnology. 2023;21(1):272. doi:10.1186/s12951-023-02044-5

159. Gehrke L, Gonçalves VDR, Andrae D, Rasko T, Ho P, Einsele H, et al. Current non-viral-based strategies to manufacture CAR-T cells. Int J Mol Sci. 2024;25(24):13685. doi:10.3390/ijms252413685

160. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016;126(9):3363-3376. doi:10.1172/JCI86721

161. Zhang Y, Zhang Z, Ding Y, Fang Y, Wang P, Chu W, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021;147(12):3725-3734. doi:10.1007/s00432-021-03613-7

162. Campelo SN, Huang PH, Buie CR, Davalos RV. Recent advancements in electroporation technologies: from bench to clinic. Annu Rev Biomed Eng. 2023;25:77-100. doi:10.1146/annurev-bioeng-110220-023800

163. Muralidharan A, Boukany PE. Electrotransfer for nucleic acid and protein delivery. Trends Biotechnol. 2024;42(6):780-798. doi:10.1016/j.tibtech.2023.11.009

164. Samal SK, Dash M, Van Vlierberghe S, Kaplan DL, Chiellini E, van Blitterswijk C, et al. Cationic polymers and their therapeutic potential. Chem Soc Rev. 2012;41(21):7147-7194. doi:10.1039/c2cs35094g

165. Sun B, Wu W, Narasipura EA, Ma Y, Yu C, Fenton OS, et al. Engineering nanoparticle toolkits for mRNA delivery. Adv Drug Deliv Rev. 2023;200:115042. doi:10.1016/j.addr.2023.115042

166. Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91-96. doi:10.1126/science.abm0594

167. Geng G, Xu Y, Hu Z, Wang H, Chen X, Yuan W, et al. Viral and non-viral vectors in gene therapy: current state and clinical perspectives. EBioMedicine. 2025;118:105834. doi:10.1016/j.ebiom.2025.105834

168. Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. 2026;25(2):116-137. doi:10.1038/s41573-025-01291-5

169. Wang R, Yu J, Caligiuri MA, Ma S. Optimizing in vivo CAR-T cell engineering for cancer immunotherapy. Cancer Res. 2026. doi:10.1158/0008-5472.CAN-25-3748

170. Pfeiffer A, Thalheimer FB, Hartmann S, Frank AM, Bender RR, Danisch S, et al. In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Mol Med. 2018;10(11):e9158. doi:10.15252/emmm.201809158

171. Yang P, Ma Z, Liu G, Shen Y, Bai Z, Zheng S, et al. Engineering viral vectors for in vivo CAR-T generation: advances, challenges, and opportunities. Crit Rev Oncol Hematol. 2026;221:105209. doi:10.1016/j.critrevonc.2026.105209

172. Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29-32. doi:10.1053/j.gastro.2018.03.029

173. Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311-1317. doi:10.1126/science.ads8473

174. Argueta S, Wang Y, Zhao H, Diwanji N, Gorgievski M, Cochran E, et al. In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models. Front Immunol. 2024;15:1501365. doi:10.3389/fimmu.2024.1501365

175. Metkar M, Pepin CS, Moore MJ. Tailor made: the art of therapeutic mRNA design. Nat Rev Drug Discov. 2024;23(1):67-83. doi:10.1038/s41573-023-00827-x

176. Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′ UTRs identified by cellular library screening. Mol Ther. 2019;27(4):824-836. doi:10.1016/j.ymthe.2018.12.011

177. Hu Q, Zhao H, Zhou K, Tian X, Wang Q, Hua X, et al. Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy. Signal Transduct Target Ther. 2025;10(1):411. doi:10.1038/s41392-025-02512-4

178. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223-249. doi:10.1146/annurev-pathol-042020-042741

179. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481

180. Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer. 2024;5(3):517-531. doi:10.1038/s43018-023-00709-6

181. Andreu-Saumell I, Rodriguez-Garcia A, Mühlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagué J, et al. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition. Nat Commun. 2024;15(1):3552. doi:10.1038/s41467-024-47799-z

182. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90(7):2541-2548. PMID: 9326219

183. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124. doi:10.1038/s41573-020-0090-8

184. Kwon N, Chen YY. Overcoming solid-tumor barriers: armored CAR-T cell therapy. Trends Cancer. 2025;11(10):1019-1029. doi:10.1016/j.trecan.2025.08.009

185. Rock KL, Hearn A, Chen CJ, Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol. 2005;26(3):231-246. doi:10.1007/s00281-004-0173-3

186. Citrin DE, Timmerman RD. Effects of radiotherapy in normal tissue. N Engl J Med. 2026;394(10):996-1009. doi:10.1056/NEJMra2506017

187. Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13(1):54. doi:10.1186/s13045-020-00890-6

188. Salthouse D, Novakovic K, Hilkens CMU, Ferreira AM. Interplay between biomaterials and the immune system: challenges and opportunities in regenerative medicine. Acta Biomater. 2023;155:1-18. doi:10.1016/j.actbio.2022.11.003

Schematic illustrating four models of NK cell recognition of tumor cells—identified self, missing self, induced self, and tolerance—based on the balance between inhibitory MHC class I signaling and activating receptor-ligand interactions.

Downloads

Published

2026-08-12

How to Cite

1.
Cheng W, Liu M-L, Diao Y-H, Chen B-K, Wen Y-P, Zhang C, et al. Reprogramming CAR-T Cell Therapy for Solid Tumors: Combination Strategies to Overcome Resistance. Cancer Biome Target Ther. [Internet]. 2026 Aug. 12 [cited 2026 Oct. 2];1(3):188-221. Available from: https://cancerbiometherapy.com/index.php/cbtt/article/view/47

Issue

Volume 1, Issue 3 (2026)

Section

Review

License

Copyright (c) 2026 Wei Cheng, Mei-Lan Liu, Yu-Hua Diao, Bing-Kun Chen, Yi-Peng Wen, Chi Zhang, Man-Ting Liu, Zi-Qi Shao, Jian-Yu Cai, Bihui Cao

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright
Authors publishing in Cancer Biome and Targeted Therapy retain full copyright of their work. By submitting a manuscript, authors grant the publisher (GCINC Press) a non-exclusive license to publish, distribute, and archive the article, and to identify itself as the original publisher.

License
All articles are published open access under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
https://creativecommons.org/licenses/by/4.0/. This license permits unrestricted use, distribution, reproduction, and adaptation in any medium, including for commercial purposes, provided that:

  • Proper attribution is given to the original author(s) and source,
  • A link to the license is provided, and
  • Any changes made are clearly indicated.

Author Rights
Authors retain the right to:

  • Use their article in future works (e.g., books, theses, lectures)
  • Share and archive the final published version on institutional repositories or personal websites
  • Adapt or translate their work, or authorize others to do so, with proper citation

Reuse by Third Parties
Content is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Third parties may copy, redistribute, remix, transform, and build upon the material for any purpose, including commercial use, provided that appropriate credit is given to the original author(s).

Archiving and Preservation
All articles are made freely available immediately upon publication, without embargo. Cancer Biome and Targeted Therapy is hosted on the Open Journal Systems (OJS) platform, developed by the Public Knowledge Project (PKP). The journal participates in long-term digital preservation through the PKP Preservation Network (PKP PN) using the LOCKSS system. Authors are encouraged to self-archive in institutional repositories, disciplinary archives, and preprint servers in accordance with the license terms.

 

Crossref
Scopus
Google Scholar
Europe PMC

Funding data